Clinical trials: Walking Impairment
Walking Impairment, Multiple Sclerosis
Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment
This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.
- Trial name
- NCT03436199
- Testing
- ADS-5102, 137 mg, ADS-5102, 274 mg
- Where
- 84 sites in United States, Canada
- Volunteers
- 558 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease
Post-Market Registry of AURYON Atherectomy Device in Subjects Affected With Infrainguinal Peripheral Artery Disease
The PATHFINDER Registry is a prospective, non-randomized, single arm, multicenter observational study. This pilot registry is aimed to evaluate the performance (peri-procedural) and clinical outcomes (intermediate and long-term)…
- Conditions
- Infrainguinal Peripheral Artery Disease, Peripheral Arterial Disease, PAD
- Trial name
- PATHFINDER (NCT04229563)
- Testing
- AURYON Atherectomy System
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- Angiodynamics, Inc.
Multiple Sclerosis, Walking Impairment
A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This study assessed the long-term safety and tolerability of ADS-5102 in subjects with MS and walking impairment who had completed the double-blind, placebo-controlled study of ADS-5102 in subjects with MS (ADS-AMT-301).
- Trial name
- NCT03567057
- Testing
- ADS-5102, 274 mg
- Where
- 92 sites in United States, Canada
- Volunteers
- 424 people
- Sponsor
- Adamas Pharmaceuticals, Inc.